Unexplained severe Coombs-negative hemolytic anemia during treatment of refractory chronic lymphocytic leukemia with alemtuzumab.
Haematology Division, Tor Vergata University, Sant'Eugenio Hospital, Piazzale dell'Umanesimo 10, 00144, Rome, Italy, pniscola@gmail.com.
Pasquale
P
Niscola
Dario
D
Ragusa
Laura
L
Scaramucci
Marco
M
Giovannini
Daniela
D
Piccioni
Andrea
A
Tendas
Alessio
A
Perrotti
Paolo
P
de Fabritiis
Giovanni
G
Del Poeta
D000208:Acute Disease; D000368:Aged; D000074323:Alemtuzumab; D000743:Anemia, Hemolytic / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D018958:CD55 Antigens / Q000235:genetics / Q000276:immunology; D018957:CD59 Antigens / Q000235:genetics / Q000276:immunology; D003298:Coombs Test; D015536:Down-Regulation; D005260:Female; D015870:Gene Expression; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018958:CD55 Antigens; D018957:CD59 Antigens; C051590:CD59 protein, human; D000074323:Alemtuzumab